Opus Genetics (IRD)
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
$5.12
After-hours close−0.03 (−0.57%)
At close$5.15(−1.34%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 2 | 2 | 1 | 4 | 4 | 4 | 3 | 3 | 4 | 2 | 1 |
| Cost of revenue | 0 | 5 | 0 | 0 | 0 | 8 | 0 | 6 | 0 | 0 | 0 | 0 |
| Gross profit | 12 | −3 | 2 | 1 | 4 | −3 | 4 | −3 | 3 | 4 | 2 | 1 |
| 6 | 2 | 9 | 9 | 12 | 35 | 14 | 6 | 11 | 15 | 17 | 17 | |
| Research & development | 3 | 4 | 5 | 6 | 9 | 7 | 8 | 6 | 6 | 10 | 11 | 11 |
| 2 | 3 | 5 | 3 | 3 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 3 | 5 | 3 | 3 | 7 | 6 | 6 | 5 | 5 | 6 | 6 |
| Other expenses | 0 | −5 | 0 | 0 | 0 | 20 | 0 | −6 | 0 | 0 | 0 | 0 |
| Operating income | 6 | −5 | −8 | −8 | −8 | −38 | −10 | −9 | −8 | −11 | −14 | −16 |
| −1 | 1 | 1 | 1 | 0 | 3 | 2 | 1 | −9 | −5 | −51 | 8 | |
| Interest income | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| Other non-operating income | −1 | −1 | −1 | −1 | 0 | −28 | −3 | −2 | 9 | 4 | 51 | −9 |
| Income before tax | 6 | −5 | −7 | −8 | −8 | −35 | −8 | −7 | −17 | −17 | −66 | −8 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 6 | −5 | −7 | −8 | −8 | −35 | −8 | −7 | −17 | −17 | −66 | −8 |
| Net income | 6 | −5 | −7 | −8 | −8 | −35 | −8 | −7 | −17 | −17 | −66 | −8 |
| EPS, basic | $0.26 | −$0.22 | −$0.29 | −$0.30 | −$0.29 | −$1.11 | −$0.24 | −$0.12 | −$0.25 | −$0.19 | −$0.75 | −$0.08 |
| EPS, diluted | $0.25 | −$0.22 | −$0.29 | −$0.30 | −$0.29 | −$1.11 | −$0.24 | −$0.12 | −$0.25 | −$0.19 | −$0.75 | −$0.08 |
| Weighted average shares, basic | 21 | 22 | 25 | 26 | 26 | 32 | 34 | 63 | 71 | 622 | 869 | 95 |
| Weighted average shares, diluted | 22 | 22 | 25 | 26 | 26 | 32 | 34 | 63 | 71 | 622 | 869 | 111 |
| EBITDA | 7 | −5 | −7 | −8 | −8 | −10 | −7 | −7 | −17 | −15 | −65 | −8 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 7 | −5 | −7 | −8 | −8 | −10 | −7 | −7 | −17 | −15 | −65 | −8 |